Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics PLC, an innovative pharmaceutical company, has reported a significant financial turnaround with its 2023 revenue reaching $17.5 million—a 2.8-fold increase from the previous year, driven by a surge in Accrufer prescriptions. The company’s operating loss has also been reduced from $49.8 million in FY22 to $31.3 million in FY23. The positive trajectory is underpinned by the launch of Accrufer in the U.S., strategic partnerships, and a focus on addressing the unmet medical need for iron deficiency treatments.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
